Sclerostin Linked to Vascular Disease in Type 2 Diabetes

Serum levels higher in patients with both type 2 diabetes and atherosclerotic disease

MONDAY, Jan. 28 (HealthDay News) -- Circulating levels of the Wnt/β-catenin signaling inhibitor sclerostin are higher in patients with type 2 diabetes who also have atherosclerotic disease, according to a study published online Jan. 3 in Diabetes Care.

Noting that Wnt/β-catenin signaling is related to the pathology of various diseases, Sonia Morales-Santana, Ph.D., from the Hospital Universitario San Cecilio in Granada, Spain, and colleagues measured serum sclerostin levels in 78 patients with type 2 diabetes mellitus, of whom 44 had atherosclerotic disease.

The researchers found that patients with atherosclerotic disease had significantly higher serum sclerostin levels, with a 4 percent increase in the risk of atherosclerotic disease for each 1 pmol/L increase in sclerostin. A sclerostin cut-off of 42.3 pmol/L could detect an increased risk of atherosclerotic disease with a sensitivity of 69 percent and a specificity of 54.8 percent. Higher sclerostin levels were associated with abnormal intima-media thickness and aortic calcification in both men and women, and with carotid plaques in men only. Homocysteine levels and intima-media thickness were positively correlated with sclerostin.

"Circulating sclerostin is increased in type 2 diabetes mellitus patients with atherosclerotic lesions," Morales-Santana and colleagues conclude.

Full Text (subscription or payment may be required)

Health News Copyright © 2013 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events